Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Mar 24
D/A
$3.30 mm in debt, sold $3.30 mm, 1 investor
21 Feb 24
D
Exempt offering of security
20 Feb 24
8-K
Entry into a Material Definitive Agreement
20 Feb 24
8-K
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
9 Feb 24
8-K
Regulation FD Disclosure
25 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
10 Jan 24
8-K
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating
10 Jan 24
DFAN14A
Additional proxy materials by non-management
3 Jan 24
DEFA14A
Additional proxy soliciting materials
29 Dec 23
DEFA14A
Additional proxy soliciting materials
28 Nov 23
DEFA14A
Additional proxy soliciting materials
20 Nov 23
DFAN14A
Additional proxy materials by non-management
20 Nov 23
DEFA14A
Additional proxy soliciting materials
20 Nov 23
DFAN14A
Additional proxy materials by non-management
16 Nov 23
8-K
Regulation FD Disclosure
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEFA14A
Additional proxy soliciting materials
8 Nov 23
8-K
Regulation FD Disclosure
8 Nov 23
DEFA14A
Additional proxy soliciting materials
7 Nov 23
DEFC14A
Proxy in contested solicitation
6 Nov 23
DEFC14A
Proxy in contested solicitation
1 Nov 23
PRER14A
Preliminary revised proxy
24 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
UPLOAD
Letter from SEC
20 Oct 23
UPLOAD
Letter from SEC
19 Oct 23
PREC14A
Preliminary proxy with contested solicitation
13 Oct 23
PREC14A
Preliminary proxy with contested solicitation
10 Oct 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
8-K
Regulation FD Disclosure
22 Sep 23
DFAN14A
Additional proxy materials by non-management
28 Aug 23
DEFA14A
Additional proxy soliciting materials
23 Aug 23
8-K
Regulation FD Disclosure
23 Aug 23
8-K
Regulation FD Disclosure
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Regulation FD Disclosure
10 Jul 23
S-8
Registration of securities for employees
3 Jul 23
8-K
Regulation FD Disclosure
27 Jun 23
8-K
Entry into a Material Definitive Agreement
30 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
Latest ownership filings
4
Peter W Rodino III
27 Mar 24
4
Thomas K Equels
27 Mar 24
4
NANCY BRYAN
22 Mar 24
4
STEWART APPELROUTH
18 Mar 24
4
Peter W Rodino III
18 Mar 24
4
Thomas K Equels
18 Mar 24
SC 13D/A
Deutsch Todd
3 Jan 24
4
Thomas K Equels
27 Nov 23
4
Thomas K Equels
29 Sep 23
SC 13D/A
Deutsch Todd
28 Aug 23
4
Thomas K Equels
25 Aug 23
4
Thomas K Equels
24 Aug 23
SC 13D/A
Deutsch Todd
7 Aug 23
SC 13D
Deutsch Todd
27 Jul 23
4
Thomas K Equels
17 Jul 23
3
NANCY BRYAN
12 Apr 23
4
STEWART APPELROUTH
10 Mar 23
4
STEWART APPELROUTH
4 Jan 23
4
Thomas K Equels
4 Jan 23
4
Peter W Rodino III
4 Jan 23
4
ELLEN M LINTAL
3 Jan 23
4
Peter W Rodino III
2 Dec 22
4
STEWART APPELROUTH
2 Dec 22
4
WILLIAM M MITCHELL
2 Dec 22
4
Thomas K Equels
2 Dec 22
3
Kirko Kirkov
13 Sep 22
4
Thomas K Equels
18 Jul 22
4
STEWART APPELROUTH
27 Apr 22
4
Peter W Rodino III
26 Apr 22
4
Thomas K Equels
26 Apr 22
3
Robert IV Dickey
4 Apr 22
4
Peter W Rodino III
4 Mar 22
4
WILLIAM M MITCHELL
4 Mar 22
4
ELLEN M LINTAL
4 Mar 22
4
Thomas K Equels
4 Mar 22
4
STEWART APPELROUTH
4 Mar 22
4/A
Thomas K Equels
13 Dec 21
4
Thomas K Equels
13 Dec 21
4
Thomas K Equels
10 Dec 21
4
III PETER W. RODINO
30 Nov 21